BioNTech Se
Q1 2023 Earnings Call
May 08, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to the BioNTech first quarter 2023 update call. I would like to hand the call over to Dr. Victoria Meissner, vice president of strategy and investor relations. Please go ahead.
Victoria Meissner -- Vice President, Strategy and Investor Relations
Good morning and afternoon. My name is Victoria Meissner, and I'm the new head of investor relations at BioNTech. I'm a medical doctor by training and have recently joined BioNTech from Healthcare Investment Banking at Jefferies. I look forward to working with you on the corporate side.
Thank you for joining us today for BioNTech's first quarter 2023 earnings call. As a brief reminder, the slides that accompany this call and the first quarter 2023 press release that was issued this morning can be found in the investors section of our website. As outlined on Slide 2, you can see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings made with U.S.
Securities and Exchange Commission. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. On Slides 3 and 4, you can see detailed safety information regarding our COVID-19 vaccine. On Slide 5, you can find the agenda for today's call.
Today, I'm joined by the following members of BioNTech's management team: our CEO and co-founder, Uğur Şahin; Ozlem Tureci, our chief medical officer and co-founder; Jens Holstein, our chief financial officer; and Ryan Richardson, our chief strategy officer. I would like to turn the call over to Uğur Şahin.
Uğur Şahin -- Co-Founder and Chief Executive Officer
Thank you, Victoria. Good morning and good afternoon and a warm welcome to all the call participants. We appreciate your continued support. Today, I will summarize our first quarter 2023 highlights and priorities before I pass the call over to my team to provide further details.
Let me reiterate our strategic goals for 2023 and highlight our first quarter and recent achievements. First, to expand and sustain our leadership in COVID-19 with Pfizer by advancing our next-generation vaccine candidate, developing combination vaccines, and advancing key Comirnaty features. This quarter, we maintained our strong COVID-19 vaccine market position, supported by key label expansions in regions around the world. This month, we published preclinical data in the journal Cell on our next-generation T-cell string vaccine component in combination with Comirnaty.